Abstract
Despite biosimilars of the granulocyte-colony stimulating factor (G-CSF) filgrastim being approved by the European Medicines Agency since 2008, there is still some debate regarding their use in related and unrelated healthy haematopoietic stem cell donors. We present a review of published experiences using biosimilar filgrastim for healthy donor mobilisation as well as the results of a survey by the World Marrow Donor Association (WMDA) of its current use by register-associated transplant and collection centres for both related and unrelated donors. A total of 1287 healthy donors and volunteers are included in the reviewed studies. The pharmacokinetics and pharmacodynamics studies show a high degree of similarity to the reference product Neupogen. Mobilisation of CD34 + cells as well as reported adverse events are also found to be comparable, although there is still a lack of long-term follow up for both Neupogen and filgrastim biosimilars. No evidence is found of a higher risk of filgrastim antibody formation using filgrastim biosimilars. Based on this increased experience, the WMDA therefore recommend that Stem Cell Donor Registries can use filgrastim biosimilars for the mobilisation of peripheral blood progenitor cells in healthy donors, provided that they are approved by national and/or regional agencies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Notes
WMDA member organisations can report using a central reporting system at https://www.wmda.info/professionals/promoting-donor-care/adverse-events-searspear/
References
European Medicines Agency: Biosimilars in the EU (Information guide for healthcare professionals). http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. Last accessed date 23 October 2017
European Medicines Agency: Biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001386.jsp&mid=WC0b01ac058002958c. Last accessed date 23 October 2017
European Medicines Agency: Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001386.jsp&mid=WC0b01ac058002958c. Last accessed date 23 October 2017
Biologics Price Competition and Innovation Act. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Last accessed date 23 October 2017
FDA: Information on biosimilars. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. Last accessed date 23 October 2017
List of FDA-approved biosimilars. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdf. Last accessed date 23 October 2017
ClinicalTrials.gov trial no. NCT00785525. https://clinicaltrials.gov/ct2/show/NCT00785525. Last accessed date 23 October 2017
Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011;96:942–7.
Liumbruno GM, Petrini C. Ethical issues and concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors. Blood transfusion. 2012;10:550–2.
Uddin S, Russell P, Farrell M, Davy B, Taylor J, Agrawal SG. Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant. Ther Adv Hematol. 2015;6:53–60.
Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, et al. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. Bone Marrow Transplant. 2014;49:880–6.
Niederwieser D. European Group for Blood and Marrow Transplantation (EBMT). Position statement. Biosimilar granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in related and unrelated donors, 2009. http://www.worldmarrow.org/fileadmin/Committees/CLWG/Biosimilars/Biosimilars_9Jan09.pdf. Last accessed 23 October 2017.
Position statement of the Japan Society for Hematopoietic Cell Transplantation regarding the use of biosimilar granulocyte-colony stimulating factors for the mobilization of hematopoietic stem cells in healthy donors 2013. http://www.jshct.com/english/. Last accessed date 23 October 2017
Gastl G, Geissler D, Geissler K, Lang A, Ludwig H, Müller M, et al. ASHO position paper on Biosimilars. memo—Magazine of European. Med Oncol. 2009;2:232–3.
Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011;96:937–42.
Gascon P, Fuhr U, Sorgel F, Kinzig-Schippers M, Makhson A, Balser S, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21:1419–29.
Azar NCS, Garnier A, et al. Use of a biosimilar G-CSF in allogeneic stem cell mobilisation. Bone Marrow Transpl Abstr Book. 2012;47(Suppl.1 s):244. Abstract p727
Ribeil J-A, Turner M, Hermine O, Blanche S, Cavazzana-Calvo M. Biosimilar compared with originator filgrastim for related-donor allogeneic stem cell mobilisation: A Prospective-Historical Control Study. Blood. 2013;122:5512.
Sorgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs. 2015;29:123–31.
Antelo ML, Zabalza A, Sanchez Anton MP, Zalba S, Aznar M, Mansilla C, et al. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio(R)). J Clin Apher. 2016;31:48–52.
Becker P, Schwebig A, Brauninger S, Bialleck H, Luxembourg B, Schulz M, et al. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance. Transfusion. 2016;56:3055–64.
Farhan R, Urbanowska E, Zborowska H, Krol M, Krol M, Torosian T, et al. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors. Ann Hematol. 2017;96:1735–9.
Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther. 2009;47:275–82.
Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs. 2009;23:43–51.
Schmitt M, Xu X, Hilgendorf I, Schneider C, Borchert K, Glaser D, et al. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplant. 2013;48:922–5.
Danylesko I, Sareli R, Bloom-Varda N, Yerushalmi R, Shem-Tov N, Shimoni A, et al. Biosimilar filgrastim (Tevagrastim, XMO2) for allogeneic hematopoietic stem cell mobilization and transplantation in patients with acute myelogenous leukemia/myelodysplastic syndromes. Biol Blood Marrow Transplant. 2016;22:277–83.
European Medicines Agency: Grastofil Public Assessment Report http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002150/WC500154066.pdf. Last accessed date 21 August 2017
Matsuguma K, Matsuki S, Sakamoto K, Shiramoto M, Nakagawa M, Kimura M, et al. A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men. Clin Pharmacol Drug Dev. 2015;4:99–104.
Crobu D, Spinetti G, Schrepfer R, Tonon G, Jotti GS, Onali P, et al. Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen(R). BMC. Pharmacol Toxicol. 2014;15:7.
Sivgin S, Karakus E, Keklik M, Zararsiz G, Solmaz M, Kaynar L, et al. Evaluation of the efficacy and safety of original filgrastim (Neupogen(R)), biosimilar filgrastim (Leucostim(R)) and Lenograstim (Granocyte(R)) in CD34( + ) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors. Transfus Apher Sci. 2016;54:410–5.
Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89:971–8.
Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89:927–33.
Lefrere F, Brignier AC, Elie C, Ribeil JA, Bernimoulin M, Aoun C, et al. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther. 2011;28:304–10.
Manko J, Walter-Croneck A, Jawniak D, Grzasko N, Gorska-Kosicka M, Cioch M, et al. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacol Rep: Pr. 2014;66:239–42.
Publicover A, Richardson DS, Davies A, Hill KS, Hurlock C, Hutchins D, et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol. 2013;162:107–11.
Schmitt M, Publicover A, Orchard KH, Gorlach M, Wang L, Schmitt A, et al. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Theranostics. 2014;4:280–9.
Remenyi P, Gopcsa L, Marton I, Reti M, Mikala G, Peto M, et al. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF. Adv Ther. 2014;31:451–60.
Schmitt M, Hoffmann JM, Lorenz K, Publicover A, Schmitt A, Nagler A. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. Vox Sang. 2016;111:178–86.
European Medicines Agency: Nivestim Public Assesment Report http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001142/WC500093664.pdf. Last accessed date 23 October 2017.
Neupogen Product Information http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.ashx. Last accessed date 23 October 2017
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Pahnke, S., Egeland, T., Halter, J. et al. Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. Bone Marrow Transplant 54, 858–866 (2019). https://doi.org/10.1038/s41409-018-0350-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0350-y
This article is cited by
-
Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation
Journal of Translational Medicine (2022)
-
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience
BioDrugs (2022)
-
Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)
Supportive Care in Cancer (2022)
-
Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation
Cellular & Molecular Immunology (2021)
-
Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis
Oncology and Therapy (2020)